print_label | resize_label

Asthma resources for you and your patients

NOTE: If you are a health care professional affiliated with an employer, institution or committee or practicing in a state that places restrictions on what items you may receive from manufacturers, we ask that you not accept or download any restricted items from this site. If you are a health care provider practicing in Vermont, we are required by state law to deny you permission to download any items or review any journal articles made available on this site.

 

Here are some asthma tools and resources you can use to help your patients (or their parents) keep on top of asthma symptoms and communicate information about their condition to you more effectively.

Please click here for full Prescribing Information for PULMICORT FLEXHALER.

Tools & Resources Download

Asthma symptom tracker

ASTHMA SYMPTOM TRACKER

Parents can use this form to track their child’s symptoms and triggers before a doctor’s appointment. DOWNLOAD
Asthma symptom prevention plan

ASTHMA SYMPTOM PREVENTION PLAN

Physicians can use this form to remind patients of individual asthma triggers, symptoms, and medication doses. DOWNLOAD
How to use PULMICORT FLEXHALER® (budesonide inhalation powder, 90
mcg & 180 mcg)

HOW TO USE PULMICORT FLEXHALER

This PDF contains step-by-step instructions for how to properly use PULMICORT FLEXHALER. DOWNLOAD
Video instructions on how to use PULMICORT FLEXHALER® (budesonide
inhalation powder, 90 mcg & 180 mcg)

WATCH THE VIDEO FOR DETAILED INSTRUCTIONS ON HOW TO USE PULMICORT FLEXHALER.

 

     These documents are PDF files, which require Adobe®Reader®; click here to download this free program.

NEXT:PULMICORT FLEXHALER SAVINGS CARD

X


IMPORTANT SAFETY INFORMATION AND INDICATION

  • PULMICORT FLEXHALER is not a bronchodilator and is NOT indicated for the relief of acute bronchospasm.
  • Particular care is needed for patients who are transferred from systemically active corticosteroids to PULMICORT FLEXHALER because deaths due to adrenal insufficiency have occurred in asthmatic patients during and after transfer from systemic corticosteroids to less systemically available inhaled corticosteroids.
  • Due to possible immunosuppression, potential worsening of infections could occur. A more serious or even fatal course of chickenpox or measles can occur in susceptible patients.
  • It is possible that systemic corticosteroid effects such as hypercorticism, reduced bone mineral density, and adrenal suppression may appear in a small number of patients, particularly at higher doses.
  • Inhaled corticosteroids may cause a reduction in growth velocity. The long-term effect on final adult height is unknown.
  • Rare instances of glaucoma, increased intraocular pressure, and cataracts have been reported following the inhaled administration of corticosteroids.
  • Hypersensitivity reactions, including anaphylaxis, have been reported with budesonide.
  • PULMICORT FLEXHALER contains small amounts of lactose, which contains trace levels of milk proteins. In patients who have severe milk protein allergy (not those who are lactose intolerant) cough, wheezing, or bronchospasm may occur.
  • Adverse reactions that occurred at a rate of ≥ 1% are: nasopharyngitis, nasal congestion, pharyngitis, allergic rhinitis, viral upper respiratory tract infection, nausea, viral gastroenteritis, otitis media, and oral candidiasis.

INDICATION

  • PULMICORT FLEXHALER is indicated for the maintenance treatment of asthma as prophylactic therapy in adult and pediatric patients 6 years of age or older.

Please click here for full Prescribing Information for PULMICORT FLEXHALER.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.FDA.gov/medwatch or call 1-800-FDA-1088.